FDA
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the medicine, which was acquired in the $3.7 billion buyout of ChemoCentryx.
FEATURED STORIES
Last month, the FDA launched TrialBlazer, intended to streamline the IND path and bring early clinical trials and medical innovation home to the U.S. It’s a start, but new agency leadership must see it through.
Significant leadership instability at the FDA—compounded by continued workforce attrition—led to a slight slowdown in overall regulatory productivity in the first half of this year, but the agency has been catching up of late.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
CMV is a common and potentially serious viral infection in allogeneic HSCT recipients.
People diagnosed with the rare blood disorder known as Erdheim-Chester disease have a new treatment option.
EyeOP1 is an high-intensity focused ultrasound device that is the first non-invasive treatment for glaucoma in China.
Tianjin CanSino Biologics announced CFDA approval of its Ebola virus vaccine for China.
Alexion is set to secure even more revenue from its blockbuster drug Soliris, the most expensive drug in the world.
Big pharmas are having a good year so far in terms of FDA approvals.
A look at how the gene therapy approvals may end up confusing payers, lawmakers, and the general public at a time when the industry desperately needs clarity.
An advisory panel with the FDA gave a near unanimous support to Novo Nordisk’s diabetes drug semaglutide, a long-acting GLP-1 analogue.
Maybe timing is everything. On Aug. 28, 2017, Gilead acquired Kite for about $11.9B.
Officially, there have been four new chemical entities have been approved since our last issue.